1-3 of 3
Nahoko Nishimoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors

Masahiro Nakagawa, Munetake Shimabe, Naoko Watanabe-Okochi, Shunya Arai, Akihide Yoshimi, Akihito Shinohara, Nahoko Nishimoto, Keisuke Kataoka, Tomohiko Sato, Keiki Kumano, Yasuhito Nannya, Motoshi Ichikawa, Yoichi Imai, Mineo Kurokawa
Journal: Blood
Blood (2011) 118 (25): 6626–6637.
https://doi.org/10.1182/blood-2010-12-326710
Published: 2011
Includes: Supplemental data
Journal Articles

Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19 ARF

Nahoko Nishimoto, Shunya Arai, Motoshi Ichikawa, Masahiro Nakagawa, Susumu Goyama, Keiki Kumano, Tsuyoshi Takahashi, Yasuhiko Kamikubo, Yoichi Imai, Mineo Kurokawa
Journal: Blood
Blood (2011) 118 (9): 2541–2550.
https://doi.org/10.1182/blood-2010-10-315440
Published: 2011
Journal Articles

AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia.

Masahiro Nakagawa, Munetake Shimabe, Nahoko Nishimoto, MD, Naoko Watanabe-Okochi, Motoshi Ichikawa, Yasuhito Nannya, Yoichi Imai, Mineo Kurokawa
Journal: Blood
Blood (2009) 114 (22): 1962.
https://doi.org/10.1182/blood.V114.22.1962.1962
Published: 2009